Search
Pelecopan
go.drugbank.com/drugs/DB21573ExperimentalPelecopan is a small molecule drug. The usage of the INN stem '-copan' in the name indicates that Pelecopan is a complement receptor antagonist/complement inhibitor.
Envonalkib
go.drugbank.com/drugs/DB21585ExperimentalEnvonalkib is a small molecule drug. The usage of the INN stem '-alkib' in the name indicates that Envonalkib is a ALK (anaplastic lymphoma kinase) inhibitor.
Zurletrectinib
go.drugbank.com/drugs/DB21601ExperimentalZurletrectinib is a small molecule drug. The usage of the INN stem '-trectinib' in the name indicates that Zurletrectinib is a tropomyosin receptor kinase (TRK) inhibitor.
Rolusafine
go.drugbank.com/drugs/DB21617ExperimentalRolusafine is a small molecule drug. The usage of the INN stem '-afine' in the name indicates that Rolusafine is a antifungal squalene mono-oxygenase inhibitor.
Merigolix
go.drugbank.com/drugs/DB21628ExperimentalMerigolix is a small molecule drug. The usage of the INN stem '-golix' in the name indicates that Merigolix is a gonadotropin releasing hormone (GnRH) antagonist.
Lerzeparib
go.drugbank.com/drugs/DB21650ExperimentalLerzeparib is a small molecule drug. The usage of the INN stem '-parib' in the name indicates that Lerzeparib is a poly-ADP-Ribose polymerase inhibitor.
Nurandociguat
go.drugbank.com/drugs/DB21720InvestigationalNurandociguat is a small molecule drug. The usage of the INN stem '-ciguat' in the name indicates that Nurandociguat is a guanylate cyclase activator and stimulator.
Vidutolimod
go.drugbank.com/drugs/DB17500InvestigationalVidutolimod is a Toll-like receptor 9 (TLR9) agonist. It is an investigational cancer vaccine.
Gamgertamig
go.drugbank.com/drugs/DB22765InvestigationalOM336 is under investigation in clinical trial NCT07083960 (OM336 in Autoimmune Cytopenias).
Mezigdomide
go.drugbank.com/drugs/DB17584InvestigationalMezigdomide is under investigation in clinical trial NCT05372354 (A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants